{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:12:54Z","timestamp":1793873574418,"version":"4.6.1"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Association of British Neurologists (ABN) Clinical Research"},{"name":"Guarantors of Brain"},{"name":"Irish Institute of Clinical Neuroscience research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Neurofilament levels are elevated in many neurodegenerative diseases and have shown promise as diagnostic and prognostic biomarkers in Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neuron Disease (MND). This study assesses serum neurofilament light (NFL) and neurofilament heavy (NFH) chain concentrations in patients with ALS, other variants of motor neuron disease such as Progressive Muscular Atrophy (PMA) and Primary Lateral Sclerosis (PLS), and a range of other neurological diseases. It aims to evaluate the use of NFL and NFH to differentiate these conditions and for the prognosis of MND disease progression. NFL and NFH levels were quantified using electrochemiluminescence immunoassays (ECLIA). Both were elevated in 47 patients with MND compared to 34 patients with other neurological diseases and 33 healthy controls. NFL was able to differentiate patients with MND from the other groups with a Receiver Operating Characteristic (ROC) curve area under the curve (AUC) of 0.90 (p &lt; 0.001). NFL correlated with the rate of disease progression in MND (rho 0.758, p &lt; 0.001) and with the ALS Functional Rating Scale (rho \u22120.335, p = 0.021). NFL levels were higher in patients with ALS compared to both PMA (p = 0.032) and PLS (p = 0.012) and were able to distinguish ALS from both PMA and PLS with a ROC curve AUC of 0.767 (p = 0.005). These findings support the use of serum NFL to help diagnose and differentiate types of MND, in addition to providing prognostic information to patients and their families.<\/jats:p>","DOI":"10.3390\/life13061301","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T01:40:56Z","timestamp":1685583656000},"page":"1301","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-598X","authenticated-orcid":false,"given":"Gavin","family":"McCluskey","sequence":"first","affiliation":[{"name":"Personalised Medicine Centre, School of Medicine, Ulster University, Derry BT47 6SB, UK"},{"name":"Department of Neurology, Royal Victoria Hospital, Belfast BT12 6BA, UK"},{"name":"Department of Neurology, Altnagelvin Hospital, Derry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Victoria Hospital, Belfast BT12 6BA, UK"},{"name":"Faculty of Medicine, Health & Life Sciences, Queen\u2019s University, Belfast BT9 6AG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Donaghy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Altnagelvin Hospital, Derry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McConville","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Victoria Hospital, Belfast BT12 6BA, UK"},{"name":"Department of Neurology, Ulster Hospital, Belfast BT16 1RH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark O.","family":"McCarron","sequence":"additional","affiliation":[{"name":"Department of Neurology, Altnagelvin Hospital, Derry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferghal","family":"McVerry","sequence":"additional","affiliation":[{"name":"Department of Neurology, Altnagelvin Hospital, Derry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2239-9094","authenticated-orcid":false,"given":"William","family":"Duddy","sequence":"additional","affiliation":[{"name":"Personalised Medicine Centre, School of Medicine, Ulster University, Derry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-5426","authenticated-orcid":false,"given":"Stephanie","family":"Duguez","sequence":"additional","affiliation":[{"name":"Personalised Medicine Centre, School of Medicine, Ulster University, Derry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"ref_1","first-page":"310","article-title":"Prognostic factors in ALS: A critical review","volume":"5\u20136","author":"Logroscino","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.CON.0000455886.14298.a4","article-title":"ALS and other motor neuron diseases","volume":"20","author":"Tiryaki","year":"2014","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000058901.75728.4E","article-title":"Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS","volume":"60","author":"Ince","year":"2003","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1212\/WNL.0b013e3181c1dea3","article-title":"Study of 962 patients indicates progressive muscular atrophy is a form of ALS","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"ref_5","first-page":"141","article-title":"Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes","volume":"90","author":"Rustemeijer","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1212\/01.wnl.0000200962.94777.71","article-title":"The natural history of primary lateral sclerosis","volume":"66","author":"Gordon","year":"2006","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/ene.15172","article-title":"Epidemiology and survival trends of motor neurone disease in Northern Ireland from 2015 to 2019","volume":"29","author":"McCluskey","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2019-322541","article-title":"Primary lateral sclerosis: Consensus diagnostic criteria","volume":"91","author":"Turner","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fneur.2019.00291","article-title":"Biomarkers in Motor Neuron Disease: A State of the Art Review","volume":"10","author":"Verber","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fneur.2019.00400","article-title":"A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS","volume":"10","author":"Vijayakumar","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1610","DOI":"10.1212\/WNL.0000000000007242","article-title":"Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials","volume":"92","author":"Berg","year":"2019","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13024-020-00406-3","article-title":"Neurofilaments in motor neuron disorders: Towards promising diagnostic and prognostic biomarkers","volume":"15","author":"Zucchi","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.conb.2020.02.001","article-title":"Neurofilaments in disease: What do we know?","volume":"61","author":"Gordon","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e000143","DOI":"10.1136\/bmjno-2021-000143","article-title":"Correlation between CSF and blood neurofilament light chain protein: A systematic review and meta-analysis","volume":"3","author":"Alagaratnam","year":"2021","journal-title":"BMJ Neurol. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_16","first-page":"1308","article-title":"Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis","volume":"20","author":"Kouchakim","year":"2021","journal-title":"EXCLI J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.neubiorev.2019.04.014","article-title":"Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis","volume":"102","author":"Zhao","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"689938","DOI":"10.3389\/fnins.2021.689938","article-title":"Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies","volume":"15","author":"Yuan","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"679199","DOI":"10.3389\/fnins.2021.679199","article-title":"Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","volume":"15","author":"Verde","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","article-title":"Diagnostic and Prognostic Performance of Neurofilaments in ALS","volume":"9","author":"Poesen","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gagliardi, D., Meneri, M., Saccomanno, D., Bresolin, N., Comi, G.P., and Corti, S. (2019). Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174152"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of Sodium Phenylbutyrate\u2013Taurursodiol for Amyotrophic Lateral Sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","article-title":"Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS","volume":"95","author":"Benatar","year":"2020","journal-title":"Neurology"},{"key":"ref_25","first-page":"12","article-title":"Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients","volume":"87","author":"Steinacker","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","article-title":"Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease","volume":"74","author":"Gaiani","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/nan.12511","article-title":"Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis","volume":"45","author":"Gille","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1038\/s41598-021-85395-z","article-title":"Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia","volume":"11","author":"Povedano","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/21678421.2018.1556696","article-title":"A standard operating procedure for King\u2019s ALS clinical staging","volume":"20","author":"Balendra","year":"2019","journal-title":"Amyotroph Lateral Scler Front. Degener"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","article-title":"Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS","volume":"66","author":"Kimura","year":"2006","journal-title":"Neurology"},{"key":"ref_32","unstructured":"McDonald, J.H. (2014). Handbook of Biological Statistics, Sparky House Publishing. [3rd ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/WNL.0b013e3182661d14","article-title":"Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases","volume":"79","author":"Huisman","year":"2012","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1212\/01.NXG.0000464294.88607.dd","article-title":"Phenotypic and molecular analyses of primary lateral sclerosis","volume":"1","author":"Mitsumoto","year":"2015","journal-title":"Neurol. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ncl.2015.07.005","article-title":"Progressive Muscular Atrophy","volume":"33","author":"Liewluck","year":"2015","journal-title":"Neurol. Clin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1212\/01.wnl.0000302187.20239.93","article-title":"The history of progressive muscular atrophy: Syndrome or disease?","volume":"70","author":"Visser","year":"2008","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"van Blitterswijk, M., Vlam, L., van Es, M.A., van der Pol, W.-L., Hennekam, E.A.M., Dooijes, D., Schelhaas, H.J., van der Kooi, A.J., de Visser, M., and Veldink, J.H. (2012). Genetic overlap between apparently sporadic motor neuron diseases. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048983"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver Operating Characteristic Curve in Diagnostic Test Assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Monaghan, T.F., Rahman, S.N., Agudelo, C.W., Wein, A.J., Lazar, J.M., Everaert, K., and Dmochowski, R.R. (2021). Foundational Statistical Principles in Medical Research: Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value. Medicina, 57.","DOI":"10.3390\/medicina57050503"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Abdelhak, A., Kuhle, J., and Green, A.J. (2023). Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain. JAMA Neurol.","DOI":"10.1001\/jamaneurol.2023.0394"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"fcac029","DOI":"10.1093\/braincomms\/fcac029","article-title":"Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain","volume":"4","author":"Thompson","year":"2022","journal-title":"Brain Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12883-020-02004-8","article-title":"Discussing personalized prognosis in amyotrophic lateral sclerosis: Development of a communication guide","volume":"20","author":"Kruithof","year":"2020","journal-title":"BMC Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"van Eenennaam, R.M., Koppenol, L.S., Kruithof, W.J., Reenen, E.T.K.-V., Pieters, S., van Es, M.A., Berg, L.H.v.D., Visser-Meily, J.M.A., and Beelen, A. (2021). Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study. Brain Sci., 11.","DOI":"10.3390\/brainsci11121597"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series","volume":"23","author":"Alves","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"753242","DOI":"10.3389\/fnagi.2021.753242","article-title":"Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study","volume":"13","author":"Vacchiano","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.24980","article-title":"Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF 72 -associated amyotrophic lateral sclerosis","volume":"82","author":"Gendron","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/JND-210735","article-title":"Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen","volume":"9","author":"Rich","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1212\/WNL.0000000000007097","article-title":"Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy","volume":"92","author":"Lombardi","year":"2019","journal-title":"Neurology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jnnp-2019-320624","article-title":"Plasma pNfH levels differentiate SBMA from ALS","volume":"91","author":"Lombardi","year":"2020","journal-title":"J. Neurol. Neurosurg Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"586610","DOI":"10.3389\/fneur.2020.586610","article-title":"Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy","volume":"11","author":"Millere","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/annrheumdis-2017-212045","article-title":"Serum neurofilament light chain: A biomarker of neuronal injury in vasculitic neuropathy","volume":"77","author":"Bischof","year":"2017","journal-title":"Ann. Rheum. Dis."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1301\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:46:32Z","timestamp":1760125592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["life13061301"],"URL":"https:\/\/doi.org\/10.3390\/life13061301","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}